COVID-19, the infectious disease caused by SARS-CoV-2, is rapidly affecting humans around the globe. While initial epidemiological data have focused on cases that resulted in severe respiratory disease seen predominantly in adults, little information regarding the infection burden in children is available. This is complicated by the observation that many virologically confirmed cases in children are asymptomatic (Dong et al, Pediatrics, PMID 32179660). Undocumented, and likely infectious, cases could result in exposure to a far greater proportion of the community than would otherwise occur. Indeed, it has been proposed that undocumented (or silent) infections are the source for almost 80% of documented infections (Li et al, Science, PMID 32179701); thus, it is critical to determine the silent and symptomatic infection rate in children. The purpose of this project is to develop, implement, and report on a surveillance study that will enroll and prospectively observe eligible children who are current participants in NIH/NIAID/DAIT-funded pediatric research studies and their family members. Many of these studies are focused on populations of children with asthma or other atopic conditions. The primary objective of this study will be to determine the incidence of SARS-CoV-2 infection (detection of virus in nasal secretions and stool and antibodies to the virus in blood) over time in children and their household contacts (caregivers and siblings).

Public Health Relevance

This project will contribute new information to our understanding of COVID-19 infection rates and transmission, including asymptomatic infections, and will allow a comparison of COVID-19 infection and its impact on children with asthma and other atopic conditions versus children without those conditions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Program Project or Center with Complex Structure Cooperative Agreement (UM2)
Project #
3UM2AI117870-06S1
Application #
10141636
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Thomas, Leighton A
Project Start
2020-05-08
Project End
2021-04-30
Budget Start
2020-05-08
Budget End
2021-04-30
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Rho Federal Systems Division, Inc.
Department
Type
DUNS #
362726007
City
Durham
State
NC
Country
United States
Zip Code
27713
Calabrese, Sarah K; Earnshaw, Valerie A; Krakower, Douglas S et al. (2018) A Closer Look at Racism and Heterosexism in Medical Students' Clinical Decision-Making Related to HIV Pre-Exposure Prophylaxis (PrEP): Implications for PrEP Education. AIDS Behav 22:1122-1138
Gill, Michelle A; Liu, Andrew H; Calatroni, Agustin et al. (2018) Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol 141:1735-1743.e9
Wildfire, Jeremy; Bailey, Ryan; Krouse, Rebecca Z et al. (2018) The Safety Explorer Suite: Interactive Safety Monitoring for Clinical Trials. Ther Innov Regul Sci 52:696-700
Simpson, Eric L; Villarreal, Miguel; Jepson, Brett et al. (2018) Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype. J Invest Dermatol 138:2224-2233
Altman, Matthew C; Whalen, Elizabeth; Togias, Alkis et al. (2018) Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. J Allergy Clin Immunol 142:1856-1866
Gergen, Peter J; Mitchell, Herman E; Calatroni, Agustin et al. (2018) Sensitization and Exposure to Pets: The Effect on Asthma Morbidity in the US Population. J Allergy Clin Immunol Pract 6:101-107.e2
du Toit, George; Sayre, Peter H; Roberts, Graham et al. (2018) Allergen specificity of early peanut consumption and effect on development of allergic disease in the Learning Early About Peanut Allergy study cohort. J Allergy Clin Immunol 141:1343-1353
Calabrese, Sarah K; Krakower, Douglas S; Mayer, Kenneth H (2017) Integrating HIV Preexposure Prophylaxis (PrEP) Into Routine Preventive Health Care to Avoid Exacerbating Disparities. Am J Public Health 107:1883-1889
Scadding, Guy W; Calderon, Moises A; Shamji, Mohamed H et al. (2017) Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial. JAMA 317:615-625
Hoch, Heather E; Calatroni, Agustin; West, Joseph B et al. (2017) Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index. J Allergy Clin Immunol 140:1130-1137.e5

Showing the most recent 10 out of 33 publications